Launching its first European therapy centre in the Netherlands in early 2021, Field Trip Health is providing psychedelic healing experiences using truffles.
Dalriada will be leveraging atai Life Science’s newly launched Invyxis platform to establish and rapidly advance a pipeline of new chemical entities (NCEs) in mental health.
The Multidisciplinary Association for Psychedelic Studies (MAPS) has been granted the Innovation Passport for MDMA as an adjunct to therapy for post-traumatic stress disorder (PTSD).
Psychedelics manufacturer Psygen has received the dealer’s license for LSD, MDMA, psilocybin, psilocin, DMT, 2C-B and mescaline.
A review has shown that ketamine therapy is able to rapidly reduce symptoms of depression and suicidal thoughts in the short-term.
A new collaboration is aiming to develop psychedelic medicines to address the unique needs of people living with a variety of mental health conditions.
Results from a new study have demonstrated that 10mg or 25mg doses of psilocybin have no long- or short-term detrimental effects in healthy individuals.
UK company Clerkenwell Health is working to develop a gold standard in the delivery of psychedelic care.
Co-founder and CEO Anthony Tennyson spoke to Psychedelic Health about Awakn’s mission to transform mental health and addiction care through psychedelics.
With the “one-size-fits-all” approach being the norm in the psychiatric industry, HMNC Brain Health is aiming to shake this up through targeted and personalised therapies powered...